zoledronic acid has been researched along with Disease Exacerbation in 103 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 33 (32.04) | 29.6817 |
| 2010's | 63 (61.17) | 24.3611 |
| 2020's | 7 (6.80) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, W; Dong, N; Hu, A; Qi, Y; Xiang, S; Xiao, J; Zhang, P; Zou, D | 1 |
| Aitken, D; Bowes, MA; Cai, G; Cicuttini, F; Conaghan, PG; Hill, C; Jones, G; Laslett, LL; March, L; Winzenberg, T; Wluka, AE | 1 |
| Ding, Y; Fu, GT; Li, CC; Lin, LJ; Lin, SP; Liu, S; Shen, J; Sheng, PY; Wang, K; Xue, YL; Zhang, JX; Zheng, QJ | 1 |
| Reid, IR | 1 |
| Ando, Y; Arai, E; Hase, T; Ikuta, K; Ishiguro, N; Kikumori, T; Maeda, O; Mitsuma, A; Nishida, Y; Shimokata, T; Sugishita, M; Urakawa, H | 1 |
| Marmolejo, D; Mirallas, O; Valdivia, A; Vieito, M | 1 |
| Bourlon, C; Bourlon, MT; Carretero-Gonzalez, A; Carril-Ajuria, L; Castellano, D; de Velasco, G; Martin-Soberon, M; Remolina-Bonilla, YA | 1 |
| Buda, G; Carulli, G; Dalla Palma, B; Fazzi, R; Galimberti, S; Giuliani, N; Morganti, R; Notarfranchi, L; Petrini, I | 1 |
| Ahn, JH; Choi, IS; Choi, YJ; Jung, KH; Kang, SY; Kim, HJ; Kim, HS; Kim, HY; Kim, JW; Lee, KE; Lee, KH; Lee, S; Oh, HS; Park, IH; Park, KH; Park, KU; Park, YH; Seo, JH; Yoo, J | 1 |
| Bulsara, M; Denham, JW; Ebert, MA; Haworth, A; Joseph, DJ; Kearvell, R; Kennedy, A; Marcello, M; Steigler, A | 1 |
| Amling, M; Butscheidt, S; Rolvien, T; Zustin, J | 1 |
| Bell, R; Bertelli, G; Bowman, A; Brown, J; Burkinshaw, R; Cameron, D; Coleman, R; Gossiel, F; Gregory, W; Hanby, A; Hinsley, S; Maccon, K; Marshall, H; Rathbone, E; Shulver, H; Thandar, H | 1 |
| Cao, Q; Chen, X; Dong, C; Huang, J; Huang, P; Liao, R; Ren, G; Tan, Y; Wang, L; Wu, X | 1 |
| Burdett, S; Carpenter, JR; Clarke, NW; Fisher, DJ; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LH; Spears, MR; Sweeney, CJ; Sydes, MR; Tierney, JF; Vale, CL; White, IR | 1 |
| Alexander, S; De-Juan-Pardo, EM; Dondossola, E; Filippini, S; Friedl, P; Hoffman, RM; Holzapfel, BM; Hutmacher, DW; Logothetis, CJ; Navone, N; Starbuck, MW | 1 |
| Ang, C; Antipin, Y; Bangi, E; Bhardwaj, A; Cagan, RL; Chen, R; Donovan, M; Gruszczynski, N; Hecht, C; Kim, S; Laspina, D; Lau, CY; Malyshev, D; Misiukiewicz, K; Moe, AS; Posner, MR; Rainey, H; Schadt, EE; Sebra, R; Selkridge, I; Smibert, P; Sung, M; Taik, P; Teague, AG; Uzilov, AV; Wilck, E; Yon, WJ; Yum, K | 1 |
| Arenare, L; Barni, S; Cinieri, S; Daniele, G; De Laurentiis, M; De Maio, E; de Matteis, A; De Placido, S; Del Mastro, L; Di Rella, F; Fabbri, A; Forestieri, V; Gallo, C; Gori, S; Gravina, A; Ibrahim, T; Iodice, G; Landi, G; Lauria, R; Mosconi, AM; Normanno, N; Nuzzo, F; Orditura, M; Pacilio, C; Perrone, F; Piccirillo, MC; Putzu, C; Ribecco, AS; Riccardi, F; Rossi, E; Simeon, V; Tinessa, V | 1 |
| Alcaraz, A; Álvarez-Ossorio, JL; Anido, U; Bellmunt, J; Calderero, V; Carles, J; Comet-Batlle, J; Constela, M; Contreras, JA; de la Piedra, C; del Alba, AG; Delgado, D; Esteban, E; Fernández, JM; García-Escudero, A; Gómez-Caamano, A; Gómez-Veiga, F; González-Enguita, C; González-Gragera, B; Lara, PC; Lassa, A; Mahillo-Fernández, I; Mañas, A; Martín-Fernández, M; Martínez-Javaloyas, JM; Méndez, MJ; Meseguer, C; Morote, J; Murias, A; Quicios, C; Reynes, G; Ribal, MJ; Rodriguez, B; Rubio, G; Samper, P; San José, LA; Sánchez, E; Segarra, J; Solsona, E; Tabernero, AJ; Unda, M; Vázquez, F; Virizuela, JA | 1 |
| Alcaraz, A; Alvarez-Ossorio, JL; Bellmunt, J; Calderero, V; Carles, J; Chirivella, I; Climent, M; Comet-Batlle, J; Contreras, JA; de la Piedra, C; Esteban, E; González-Del Alba, A; González-Enguita, C; González-Gragera, B; González-López, R; Lara, PC; Lassa, A; León-Mateos, L; Mahillo-Fernández, I; Mañas, A; Mellado, B; Méndez, MJ; Meseguer, C; Morote, J; Murias, A; Samper, P; Segarra, J; Unda, M; Vázquez, F | 1 |
| Hahn, NM; Kirkpatrick, K; Sharma, J; Sweeney, CJ; Yiannoutsos, CT | 1 |
| Costa, L; Dansey, R; Feng, A; Henry, D; Hirsh, V; Hungria, V; Jun, S; Scagliotti, G; Smith, G; Vadhan-Raj, S; von Moos, R; Woll, PJ; Yeh, H | 1 |
| Bhoopalam, N; Halabi, S; Hauke, RJ; Hussain, A; Kelly, WK; Monk, JP; Morris, M; Ryan, CJ; Saad, F; Sanford, B; Saylor, P; Small, EJ; Smith, MR; Stadler, W; Vogelzang, N | 1 |
| Amiaud, J; Battaglia, S; Charrier, C; Gouin, F; Heymann, D; Kim, PP; Lamoureux, F; Odri, G; Redini, F | 1 |
| Bolat, F; Cınar, BM; Karaeminogullari, O; Ozkoc, G; Sezgin, N; Tandogan, RN | 1 |
| Antón, A; Arizcuma, A; Barnadas, A; Calvo, L; Chacón, JI; Codes, M; Crespo, C; de Juan, A; de la Piedra, C; Gavilá, J; Gómez, P; Heras, L; Luque, M; Mahillo-Fernández, I; Manso, L; Margelí, M; Martin-Fernández, M; Martinez, P; Meseguer, C; Murias, A; Perelló, A; Pérez, D; Ruiz-Borrego, M; Salvador, J; Seguí, MÁ; Tusquets, I; Zamora, P | 1 |
| Bouvet, M; Chishima, T; Endo, I; Hassanein, MK; Hiroshima, Y; Hoffman, RM; Ichikawa, Y; Maawy, A; Matsuyama, R; Menen, R; Miwa, S; Momiyama, M; Mori, R; Murakami, T; Tanaka, K; Uehara, F; Yamamoto, M; Yano, S | 1 |
| Esa, A; Hara, I; Iki, M; Imanishi, M; Kajikawa, H; Komura, T; Matsuyama, H; Nagao, K; Nishioka, T; Nozawa, M; Ogawa, T; Uejima, S; Uekado, Y; Uemura, H | 1 |
| Leung, WK; Li, CL; Lu, WW; Seneviratne, CJ; Zheng, LW; Zwahlen, RA | 1 |
| Consolini, R; Failli, A; Legitimo, A; Orsini, G; Romanini, A | 1 |
| Manabe, J; Miyata, S; Orita, Y; Sugitani, I; Takao, S; Toda, K | 1 |
| Dakhil, SR; Hines, SL; Kearns, AE; Lafky, JM; Liu, H; Loprinzi, CL; Perez, EA; Puttabasavaiah, S; Sloan, JA; Wagner-Johnston, ND | 1 |
| Burnham, JM; Chauvin, NA; Jaramillo, D; Zhao, Y | 1 |
| Daga, H; Hirashima, T; Miyamoto, N; Morishita, N; Okada, H; Okamoto, N; Otsuka, T; Sasada, S; Shiroyama, T; Suzuki, H; Taira, K; Takeda, K; Tamiya, M; Tokunaga, S | 1 |
| Huo, L; Li, CL; Lu, WW; Seneviratne, CJ; Zheng, LW | 1 |
| Gomes Filho, JE; Kobayashi, J; Kobayashi, M; Matsuda, S; Ohba, S; Sano, K; Wayama, MT; Yoshida, H; Yoshimura, H | 1 |
| Amiaud, J; Battaglia, S; Baud'huin, M; Heymann, D; Lamoureux, F; Ory, B; Quillard, T; Redini, F; Royer, BB; Verrecchia, F | 1 |
| Alzouebi, M; Amos, C; Attard, G; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; de Bono, J; Dearnaley, DP; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; James, ND; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McKinna, F; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MK; Peedell, C; Protheroe, A; Ritchie, AW; Robinson, AJ; Russell, JM; Spears, MR; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Sydes, MR; Thalmann, G; Tolan, S; Tsang, D; Wagstaff, J | 1 |
| Banks, RE; Brown, JE; Cairns, DA; Coleman, RE; Hanby, AM; Holen, I; Marshall, H; Ottewell, PD; Peng, J; Selby, PJ; Speirs, V; Westbrook, JA; Wood, SL | 1 |
| Aghaloo, TL; Bezouglaia, O; Cirelli, JA; Cunha, FQ; de Molon, RS; Dry, SM; Hsu, C; Pirih, FQ; Soundia, A; Tetradis, S | 1 |
| Brown, JE; Fizazi, K; Henry, D; Lipton, A; Saad, F; Shore, ND; Smith, MR; Spencer, A; Stopeck, AT; Warner, DJ; Zhu, L | 1 |
| Atkinson, C; Attia, J; Christie, D; Denham, JW; Duchesne, G; Holliday, EG; Joseph, D; Lamb, DS; Matthews, JH; Spry, NA; Sridharan, S; Steigler, A; Tai, KH | 1 |
| Fu, P; Li, Q; Wen, F; Yang, Y; Zhang, P | 1 |
| Guise, TA; Harhash, AA; John, SK; Kozlow, WM; Marks, AR; Mohammad, KS; Murthy, S; Niewolna, M; Regan, JN; She, Y; Waning, DL; Wright, LE | 1 |
| Laghezza, A; Lynch, CC; Neuger, AM; Sansil, SS; Shay, G; Soliman, H; Tauro, M; Tortorella, P | 1 |
| Agosto, S; Ahmadi, S; Bruder, JM; Koops, M; Toro-Tobón, D | 1 |
| Andriani, A; Balleari, E; Boccadoro, M; Bongarzoni, V; Bringhen, S; Caravita, T; D'Arena, G; Guglielmelli, T; Musto, P; Palumbo, A; Petrucci, MT; Pietrantuono, G | 1 |
| Kyrgidis, A; Teleioudis, Z; Vahtsevanos, K | 1 |
| Colombel, M | 1 |
| Merola, C; Merola, G; Montella, L; Palmieri, G; Petillo, L | 1 |
| Evdokiou, A; Findlay, DM; Hay, S; Labrinidis, A; Liapis, V; Ponomarev, V | 1 |
| Boutsikou, E; Eleftheriadou, E; Kanakis, I; Karamanos, NK; Kontakiotis, T; Lithoxopoulou, H; Tzanakakis, G; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Lipton, A; Saad, F | 1 |
| Buccheri, S; Caccamo, N; Cicero, G; D'Asaro, M; Dieli, F; Eberl, M; Guggino, G; Hayday, AC; La Mendola, C; Meraviglia, S; Orlando, V; Roberts, A; Scarpa, F; Stassi, G; Todaro, M; Vermijlen, D | 1 |
| Chen, YM; Saad, F; Tchekmedyian, NS | 1 |
| Beckmann, MW; Gnant, M; Jonat, W; Kreienberg, R; Lux, MP; Reichelt, C; Thiel, FC; Wallwiener, D | 1 |
| Eastham, JA; Saad, F | 1 |
| López-Carrizosa, MC; Pérez, AR; Samper-Ots, PM | 1 |
| Acham, S; Jakse, N; Obermayer-Pietsch, B; Rugani, P; Truschnegg, A | 1 |
| Dörnenburg, O; Heyd, R; Rabeneck, D; Tselis, N; Zamboglou, N | 1 |
| Dalbeth, N; Doyle, A; Exeter, M; Jones, P; Lloyd, R; Lobo, M; McQueen, F; Reid, IR; Robinson, E; Taylor, WJ | 1 |
| Voelker, R | 1 |
| Culver, KW; Diener, M; Guo, A; Namjoshi, M; Parikh, K; Wu, EQ; Xie, J; Yu, AP | 1 |
| Brown, HK; Brown, NJ; Coleman, RE; Cross, SS; Holen, I; Jones, M; Ottewell, PD; Rogers, TL | 1 |
| Hewson, ID | 1 |
| Bundred, N | 1 |
| Berruti, A; Buttigliero, C; Coleman, RE; Cook, R; Lee, KA; Lipton, A; Saad, F; Smith, MR; Tampellini, M | 1 |
| Abdelkarim, M; Crepin, M; Di Benedetto, M; Jais, JP; Kassis, N; Lecouvey, M; Perret, GY; Vintonenko, N | 1 |
| Clezardin, P; Coleman, R; Gnant, M; Morgan, G | 1 |
| Botteman, MF; Carter, JA; Kaura, S; Snedecor, SJ | 1 |
| Dispenzieri, A; Gertz, MA; Greipp, PR; Hassoun, H; Hayman, SR; Kumar, S; Lacy, MQ; Laumann, KM; Lust, JA; Mandrekar, SJ; Rajkumar, SV; Reeder, CB; Roy, V; Witzig, TE | 1 |
| Anagnostis, P; Anastasilakis, AD; Arsos, G; Kita, M; Moralidis, E; Papatheodorou, A; Polyzos, SA; Terpos, E | 1 |
| Boikos, SA; Hammers, HJ | 1 |
| Beuzeboc, P; Bilynskyy, B; Braun, A; Brown, JE; Charu, V; Clemens, M; Fizazi, K; Henry, DH; Jun, S; Ke, C; Lipton, A; Maroto, P; Rader, M; Richardson, GE; Saad, F; Siena, S; Stopeck, AT; Viniegra, M; Yardley, DA | 1 |
| Bohle, G; Chou, JF; Estilo, CL; Halpern, J; Hansen, HJ; Huryn, JM; Riedel, E; Tunick, S; Watters, AL; Williams, T | 1 |
| Penson, DF; Resnick, MJ | 1 |
| Barney, RB; Biskupiak, JE; Brandt, P; Gaffney, DK; Namjoshi, M; Nickman, NA; Young, J | 1 |
| Chen, B; Chin, JL; Gleason, DM; Goas, JA; Lacombe, L; Murray, R; Saad, F; Tchekmedyian, S; Venner, P; Vinholes, JJ | 1 |
| Lipton, A; Seaman, J; Zheng, M | 1 |
| Curley, T; Delacruz, A; Diani, M; Fallon, M; Fleisher, M; Flombaum, C; Kelly, WK; Morris, MJ; Scher, HI; Schwartz, L; Slovin, S; Smaletz, O; Solit, D; Zhu, A | 1 |
| La Cesa, A; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Beer, TM; Garzotto, M; Tiffany, NM; Wersinger, EM | 1 |
| Goldring, SR; Gravallese, EM | 1 |
| Forsea, AM; Geilen, CC; Müller, C; Orfanos, CE; Riebeling, C | 1 |
| Altundag, K; Altundag, O; Gunduz, M; Morandi, P | 1 |
| Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D | 1 |
| Langer, CJ | 1 |
| Barone, A; Foppiani, L; Palummeri, E; Prete, C; Senesi, B; Trasciatti, S; Veneziano, M | 1 |
| Bilhartz, DL; Cook, R; Gittelman, MC; Goessl, C; Hei, YJ; Higano, CS; Hussain, A; Kabbinavar, F; Linnartz, R; Murray, R; Saad, F; Schulman, C; Small, EJ; Smith, MR; Wynne, C; Zheng, M; Zinner, NR | 1 |
| Dunleavy, R; Liauw, W; Lih, A; Links, M; Segelov, E; Ward, R | 1 |
| De Filippo, G; Mossetti, G; Rendina, D | 1 |
| Gouin, F; Heymann, D; Ory, B; Rédini, F | 1 |
| Brown, J; Coleman, R; Cook, RJ; Hei, YJ; Lipton, A; Major, P; Saad, F; Smith, MR | 1 |
| Kantoff, P; Kaufman, DS; Michaelson, MD; Oh, WK; Smith, MR | 1 |
| Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G | 1 |
| Eickenberg, HU; Haus, U; Jung, K; Lein, M; Loening, SA; Meissner, S; Miller, K; Schmidt, K; Stephan, C; Weissbach, L; Wirth, M | 1 |
| Bodmer, M; Kummer, O; Ramazzina, C; Rätz Bravo, AE; Zysset Aschmann, Y | 1 |
| Avcu, F; Ural, AU | 1 |
| Berenson, JR; Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR; Terpos, E | 1 |
| Crescimanno, M; Flandina, C; Leto, G; Tumminello, FM | 1 |
| Chang, JW; Chou, WC; Huang, JS; Li, YY; Liaw, CC; Wang, CH; Wang, HM; Yeh, KY | 1 |
| Abelson, A | 1 |
| Birbilis, T; Gymnopoulou, E; Oikonomou, A; Prassopoulos, P | 1 |
| Larmas, M; Salo, T; Sorsa, T; Sulkala, M; Teronen, O; Tjäderhane, L; Wahlgren, J | 1 |
14 review(s) available for zoledronic acid and Disease Exacerbation
| Article | Year |
|---|---|
Recent advances in understanding and managing Paget's disease.
Topics: Clinical Trials as Topic; Diphosphonates; Disease Management; Disease Progression; Humans; Osteitis Deformans; Quality of Life; Remission Induction; Zoledronic Acid | 2019 |
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Network Meta-Analysis; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2018 |
Chronic Myeloid Leukemia Associated Hypercalcemia: A Case Report and Literature Review.
Topics: Blast Crisis; Bone Density Conservation Agents; Calcitonin; Diphosphonates; Disease Progression; Drug Therapy, Combination; Fatal Outcome; Humans; Hypercalcemia; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Zoledronic Acid | 2017 |
Bone-marker levels in patients with prostate cancer: potential correlations with outcomes.
Topics: Alkaline Phosphatase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Collagen Type I; Denosumab; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Peptides; Prognosis; Prostatic Neoplasms; RANK Ligand; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2010 |
Zoledronic acid use in patients with bone metastases from renal cell carcinoma or bladder cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Humans; Imidazoles; Kidney Neoplasms; Survival Analysis; Urinary Bladder Neoplasms; Zoledronic Acid | 2010 |
Antiresorptive therapies in oncology and their effects on cancer progression.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Controlled Clinical Trials as Topic; Denosumab; Diphosphonates; Disease Progression; Humans; Imidazoles; Neoplasm Metastasis; Neoplasms; RANK Ligand; Zoledronic Acid | 2012 |
Effects of bone-targeted agents on cancer progression and mortality.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Diphosphonates; Disease Progression; Disease-Free Survival; Female; Goserelin; Humans; Imidazoles; Male; Menopause; Neoplasms; Prostatic Neoplasms; Survival Rate; Treatment Outcome; Zoledronic Acid | 2012 |
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.
Topics: Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Disease Progression; Female; Humans; Hypocalcemia; Imidazoles; Male; Middle Aged; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome; Zoledronic Acid | 2012 |
Quality of life with advanced metastatic prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Disease Progression; Docetaxel; Health Status Indicators; Humans; Imidazoles; Male; Mitoxantrone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome; Zoledronic Acid | 2012 |
Bisphosphonates: environmental protection for the joint?
Topics: Animals; Arthritis; Arthritis, Rheumatoid; Bone Resorption; Collagen; Diphosphonates; Disease Progression; Imidazoles; Osteoclasts; Zoledronic Acid | 2004 |
Primary hyperparathyroidism and neuropsychiatric alterations in a nonagenarian woman.
Topics: Aged; Aged, 80 and over; Bone Diseases, Metabolic; Cognition Disorders; Diphosphonates; Disease Progression; Diuretics; Female; Humans; Hypercalcemia; Hyperparathyroidism; Imidazoles; Nervous System Diseases; Sodium Chloride; Treatment Outcome; Zoledronic Acid | 2005 |
[Zoledronate-associated end stage renal failure and hypocalcaemia].
Topics: Acute Kidney Injury; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Biopsy; Bone Density Conservation Agents; Calcium; Creatinine; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Hypocalcemia; Imidazoles; Kidney Failure, Chronic; Kidney Tubules; Middle Aged; Multiple Myeloma; Pamidronate; Renal Dialysis; Risk Factors; Switzerland; Time Factors; Vitamin D; Zoledronic Acid | 2007 |
Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.
Topics: Biomarkers; Bone and Bones; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Imidazoles; Multiple Myeloma; Osteolysis; Predictive Value of Tests; Risk Factors; Survival Rate; Zoledronic Acid | 2007 |
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Pamidronate; Risedronic Acid; Risk Factors; Treatment Outcome; Zoledronic Acid | 2008 |
28 trial(s) available for zoledronic acid and Disease Exacerbation
| Article | Year |
|---|---|
Effect of zoledronic acid with or without methylprednisolone on 3D bone area and bone shape in patients with symptomatic knee osteoarthritis: A post-hoc analysis of the ZAP2 trial.
Topics: Disease Progression; Female; Femur; Humans; Knee Joint; Male; Methylprednisolone; Osteoarthritis, Knee; Zoledronic Acid | 2022 |
Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Interleukin-2; Italy; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Remission Induction; Time Factors; Treatment Outcome; Zoledronic Acid | 2020 |
Association between measures of treatment quality and disease progression in prostate cancer radiotherapy: An exploratory analysis from the TROG 03.04 RADAR trial.
Topics: Adult; Aged; Androgen Antagonists; Australia; Combined Modality Therapy; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Middle Aged; New Zealand; Prostatic Neoplasms; Radiotherapy Dosage; Survival Rate; Zoledronic Acid | 2018 |
Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.
Topics: Biomarkers, Tumor; Bone and Bones; Bone Development; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Early Detection of Cancer; Female; Humans; Infusions, Intravenous; Middle Aged; Prognosis; Standard of Care; United Kingdom; Zoledronic Acid | 2018 |
Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Estrogen Antagonists; Female; Humans; Italy; Letrozole; Middle Aged; Ovary; Premenopause; Tamoxifen; Time Factors; Triptorelin Pamoate; Zoledronic Acid | 2019 |
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Diphosphonates; Disease Progression; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Predictive Value of Tests; Prognosis; Prostatic Neoplasms; Risk Factors; Survival Analysis; Zoledronic Acid | 2013 |
Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Diphosphonates; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Osteocalcin; Pamidronate; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2014 |
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Denosumab; Diphosphonates; Disease Progression; Double-Blind Method; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Multiple Myeloma; Neoplasms; Pain; Treatment Outcome; Zoledronic Acid | 2014 |
Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Diagnostic Imaging; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2014 |
Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Routes; Drug Therapy, Combination; Follow-Up Studies; Goserelin; Humans; Imidazoles; Japan; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Time Factors; Tosyl Compounds; Zoledronic Acid | 2015 |
5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
Topics: Aged; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Breast Neoplasms, Male; Chemotherapy, Adjuvant; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Imidazoles; Letrozole; Male; Middle Aged; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Tamoxifen; Triazoles; Zoledronic Acid | 2015 |
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Collagen Type I; Denosumab; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Male; Middle Aged; PAX5 Transcription Factor; Peptides; Zoledronic Acid | 2016 |
Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial.
Topics: Aged; Androgen Antagonists; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Radiosurgery; Zoledronic Acid | 2016 |
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Male; Middle Aged; Multiple Myeloma; Survival Analysis; Zoledronic Acid | 2008 |
In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
Topics: Adjuvants, Immunologic; Aged; Breast Neoplasms; Cell Proliferation; Chemokines; Cytokines; Diphosphonates; Disease Progression; Esterases; Female; Hemiterpenes; Humans; Imidazoles; Immunotherapy; Interferon-gamma; Interleukin-2; Leukocyte Common Antigens; Lymphocyte Activation; Lymphocyte Count; Lysine; Middle Aged; Mucin-1; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; Remission Induction; Salvage Therapy; T-Lymphocyte Subsets; TNF-Related Apoptosis-Inducing Ligand; Treatment Outcome; Tumor Necrosis Factor Receptor Superfamily, Member 7; Zoledronic Acid | 2010 |
Zoledronic acid does not reduce MRI erosive progression in PsA but may suppress bone oedema: the Zoledronic Acid in Psoriatic Arthritis (ZAPA) Study.
Topics: Adult; Arthritis, Psoriatic; Bone Density Conservation Agents; Bone Marrow Diseases; Diphosphonates; Disease Progression; Edema; Epidemiologic Methods; Female; Finger Joint; Humans; Imidazoles; Magnetic Resonance Imaging; Male; Middle Aged; Treatment Outcome; Wrist Joint; Zoledronic Acid | 2011 |
Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Cohort Studies; Cost-Benefit Analysis; Denosumab; Diphosphonates; Disease Progression; Drug Costs; Health Care Costs; Humans; Imidazoles; Male; Markov Chains; Models, Economic; Multivariate Analysis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Sensitivity and Specificity; United States; Zoledronic Acid | 2011 |
Prognostic role of serum parathyroid hormone levels in advanced prostate cancer patients undergoing zoledronic acid administration.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Double-Blind Method; Humans; Hyperparathyroidism, Secondary; Imidazoles; Male; Middle Aged; Multivariate Analysis; Parathyroid Hormone; Prognosis; Prostatic Neoplasms; Survival Analysis; Zoledronic Acid | 2012 |
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Imidazoles; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Prognosis; Survival Rate; Thalidomide; Zoledronic Acid | 2013 |
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Imidazoles; Infusions, Intravenous; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Zoledronic Acid | 2002 |
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Topics: Aged; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Female; Fractures, Bone; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Placebos; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2003 |
Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzamides; Bone Diseases; Bone Neoplasms; Bone Resorption; Diphosphonates; Disease Progression; Drug Therapy, Combination; Humans; Imatinib Mesylate; Imidazoles; Male; Middle Aged; Pain; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Treatment Failure; Zoledronic Acid | 2004 |
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Double-Blind Method; Follow-Up Studies; Humans; Imidazoles; Male; Placebos; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Zoledronic Acid | 2005 |
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Disease Progression; Follow-Up Studies; Humans; Imidazoles; Male; Multicenter Studies as Topic; Multivariate Analysis; Peptides; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Zoledronic Acid | 2006 |
Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Dyspnea; Edema; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Treatment Outcome; Zoledronic Acid | 2006 |
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Disease Progression; Drug Resistance; Female; Humans; Imidazoles; Middle Aged; Pain; Palliative Care; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2006 |
Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression.
Topics: Aged; Alkaline Phosphatase; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Peptide Fragments; Peptides; Procollagen; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2007 |
61 other study(ies) available for zoledronic acid and Disease Exacerbation
| Article | Year |
|---|---|
Efficacy Evaluation of Zoledronic Acid Combined with Chemotherapy in the Treatment of Lung Cancer Spinal Metastases on Computed Tomography Images on Intelligent Algorithms.
Topics: Algorithms; Alopecia; Bayes Theorem; Bone Neoplasms; Cisplatin; Disease Progression; Humans; Lung Neoplasms; Pain; Spinal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2022 |
Efficiency of Zoledronic Acid in Inhibiting Accelerated Periprosthetic Bone Loss After Cementless Total Hip Arthroplasty in Osteoporotic Patients: A Prospective, Cohort Study.
Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Disease Progression; Female; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Vitamin D; Zoledronic Acid | 2019 |
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Collagen Type I; Denosumab; Disease Progression; Female; Follow-Up Studies; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Peptides; Prognosis; Prospective Studies; Tartrate-Resistant Acid Phosphatase; Zoledronic Acid | 2020 |
Grade I meningioma with disseminated bone disease: a rare clinical phenomenon.
Topics: Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Bone Diseases; Disease Progression; Drug Therapy, Combination; Estrogen Antagonists; Fatal Outcome; Humans; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Grading; Octreotide; Pelvic Pain; Pelvis; Radiotherapy; Tamoxifen; Tomography, X-Ray Computed; Zoledronic Acid | 2020 |
Challenges of Treating a Patient With Advanced Prostate Cancer During the COVID-19 Pandemic.
Topics: Aged; Androgen Antagonists; Androstenes; Anticoagulants; Antineoplastic Agents; Betacoronavirus; Bone Density Conservation Agents; Bone Neoplasms; Cancer Pain; Coronavirus Infections; COVID-19; Disease Progression; Docetaxel; Drug Combinations; Eligibility Determination; Heparin, Low-Molecular-Weight; Humans; Intensive Care Units; Lopinavir; Male; Oxygen Inhalation Therapy; Palliative Care; Pandemics; Pneumonia, Viral; Prostatic Neoplasms, Castration-Resistant; Renal Insufficiency; Respiratory Insufficiency; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severity of Illness Index; Zoledronic Acid | 2020 |
Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13).
Topics: Adult; Aged; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Cytokines; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Taxoids; Zoledronic Acid | 2021 |
Skeletal dissemination in Paget's disease of the spine.
Topics: Alkaline Phosphatase; Diphosphonates; Disease Progression; Humans; Iatrogenic Disease; Male; Middle Aged; Osteitis Deformans; Postoperative Complications; Spine; Tomography, X-Ray Computed; Zoledronic Acid | 2018 |
Inhibition of UGT8 suppresses basal-like breast cancer progression by attenuating sulfatide-αVβ5 axis.
Topics: Animals; Biosynthetic Pathways; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Movement; Disease Progression; Female; Ganglioside Galactosyltransferase; Gene Expression Regulation, Neoplastic; Humans; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Receptors, Vitronectin; Signal Transduction; SOXE Transcription Factors; Sulfoglycosphingolipids; Survival Analysis; Up-Regulation; Zoledronic Acid | 2018 |
Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone.
Topics: Animals; Bone Marrow; Bone Neoplasms; Cathepsin K; Cell Line, Tumor; Diphosphonates; Disease Progression; Female; Humans; Intravital Microscopy; Male; Mice; Mice, Nude; Miniaturization; Osteolysis; Stromal Cells; Tissue Engineering; Tissue Scaffolds; Treatment Outcome; Zoledronic Acid | 2018 |
A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease Progression; Drosophila; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Genes, ras; Genomics; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Precision Medicine; Pyridones; Pyrimidinones; Zoledronic Acid | 2019 |
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Bone Remodeling; Carcinoma, Renal Cell; Collagen Type I; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Peptide Fragments; Procollagen; Prospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Zoledronic Acid | 2013 |
Zoledronic acid inhibits pulmonary metastasis dissemination in a preclinical model of Ewing's sarcoma via inhibition of cell migration.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Diphosphonates; Disease Models, Animal; Disease Progression; Drug Evaluation, Preclinical; Female; Humans; Imidazoles; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Sarcoma, Ewing; Tumor Burden; Tumor Cells, Cultured; Zoledronic Acid | 2014 |
Intra-articular zoledronic acid in a rat osteoarthritis model: significant reduced synovitis may indicate chondroprotective effect.
Topics: Animals; Bone Density Conservation Agents; Cartilage, Articular; Chondrocytes; Diphosphonates; Disease Models, Animal; Disease Progression; Imidazoles; Injections, Intra-Articular; Male; Osteoarthritis, Knee; Rats; Rats, Wistar; Synovial Membrane; Synovitis; Zoledronic Acid | 2015 |
Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: results from a 2-year multicentre observational study (ZOMAR study).
Topics: Biomarkers; Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Middle Aged; Neoplastic Cells, Circulating; Proportional Hazards Models; Treatment Outcome; Zoledronic Acid | 2014 |
The tumor-educated-macrophage increase of malignancy of human pancreatic cancer is prevented by zoledronic acid.
Topics: Animals; Cell Communication; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Models, Animal; Disease Progression; Heterografts; Humans; Imidazoles; Macrophages; Mice; Mitosis; Pancreatic Neoplasms; Zoledronic Acid | 2014 |
Role of periodontal disease in bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats.
Topics: Alveolar Bone Loss; Animals; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Models, Animal; Disease Progression; Female; Imidazoles; Ovariectomy; Periodontal Diseases; Random Allocation; Rats; Rats, Sprague-Dawley; X-Ray Microtomography; Zoledronic Acid | 2016 |
The effects of zoledronate on monocyte-derived dendritic cells from melanoma patients differ depending on the clinical stage of the disease.
Topics: Cell Differentiation; Cell Proliferation; Cells, Cultured; Dendritic Cells; Diphosphonates; Disease Progression; Endocytosis; Female; Humans; Imidazoles; Lipopolysaccharide Receptors; Lymphocyte Activation; Male; Melanoma; Neovascularization, Pathologic; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Helper-Inducer; Tumor Microenvironment; Zoledronic Acid | 2014 |
Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.
Topics: Adult; Aged; Alkaline Phosphatase; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Carcinoma; Collagen Type I; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Male; Middle Aged; Pain; Peptides; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Spinal Cord Compression; Thyroid Neoplasms; Zoledronic Acid | 2015 |
Aggressive Therapy Reduces Disease Activity without Skeletal Damage Progression in Chronic Nonbacterial Osteomyelitis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Bone and Bones; Bone Density Conservation Agents; Child; Diphosphonates; Disease Progression; Drug Therapy, Combination; Female; Humans; Imidazoles; Infliximab; Magnetic Resonance Imaging; Male; Methotrexate; Osteomyelitis; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Zoledronic Acid | 2015 |
Evaluation of Bone Metastasis Using Serial Measurements of Serum N-Telopeptides of Type I Collagen in Patients with Lung Cancer: A Prospective Study.
Topics: Adult; Aged; Bone Neoplasms; Collagen Type I; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Peptides; Prospective Studies; Zoledronic Acid | 2015 |
Impact of Actinomyces naeslundii on bisphosphonate-related osteonecrosis of the jaws in ovariectomized rats with periodontitis.
Topics: Actinomyces; Actinomycosis; Alveolar Bone Loss; Animals; Bacterial Load; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Cancellous Bone; Diphosphonates; Disease Models, Animal; Disease Progression; Female; Imidazoles; Mandibular Diseases; Ovariectomy; Periodontitis; Random Allocation; Rats; Rats, Sprague-Dawley; X-Ray Microtomography; Zoledronic Acid | 2015 |
Diminished Progression of Periapical Lesions with Zoledronic Acid in Ovariectomized Rats.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Progression; Female; Imidazoles; Immunohistochemistry; Osteonecrosis; Ovariectomy; Periapical Periodontitis; Rats, Wistar; X-Ray Microtomography; Zoledronic Acid | 2015 |
Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Progression; Drug Synergism; Female; HSP90 Heat-Shock Proteins; Humans; Imidazoles; Mice; Mice, Nude; Monocytes; Neoplasm Metastasis; Osteosarcoma; Signal Transduction; Xenograft Model Antitumor Assays; Zoledronic Acid | 2016 |
CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.
Topics: Adaptor Proteins, Signal Transducing; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Microfilament Proteins; Molecular Targeted Therapy; Nuclear Proteins; Odds Ratio; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Reproducibility of Results; Zoledronic Acid | 2016 |
Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.
Topics: Animals; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Diphosphonates; Disease Progression; Imaging, Three-Dimensional; Imidazoles; Male; Mandible; Maxilla; Mice, Inbred DBA; Severity of Illness Index; X-Ray Microtomography; Zoledronic Acid | 2016 |
Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Docetaxel; Humans; Imidazoles; Male; Markov Chains; Prostatic Neoplasms; Standard of Care; Taxoids; Zoledronic Acid | 2017 |
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Progression; Estradiol; Female; Humans; Imidazoles; Letrozole; Mice, Inbred BALB C; Mice, Nude; Muscle Strength; Muscle Weakness; Muscle, Skeletal; Nitriles; Osteolysis; Ovariectomy; Receptors, Estrogen; Time Factors; Triazoles; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays; Zoledronic Acid | 2017 |
Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Diphosphonates; Disease Progression; Enzyme Activation; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Models, Biological; Multimodal Imaging; Osteoclasts; Tumor Burden; Tumor Microenvironment; Zoledronic Acid | 2017 |
Re: Christian Walter, Bilal Al-Nawas, Knut A. Grötz, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008;54:1066-72.
Topics: Bone Density Conservation Agents; Diphosphonates; Disease Progression; Humans; Imidazoles; Jaw Diseases; Male; Osteonecrosis; Prevalence; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2009 |
[Prescription of bisphosphonates in prostate cancer].
Topics: Administration, Oral; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Humans; Ibandronic Acid; Imidazoles; Injections; Male; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Zoledronic Acid | 2008 |
Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis.
Topics: Adult; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Female; Histiocytosis, Langerhans-Cell; Humans; Imidazoles; Male; Middle Aged; Radionuclide Imaging; Young Adult; Zoledronic Acid | 2009 |
Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Female; Green Fluorescent Proteins; Humans; Imidazoles; Luciferases; Luminescent Measurements; Mice; Mice, Inbred BALB C; Mice, Nude; Osteoblasts; Osteolysis; Osteosarcoma; Recombinant Fusion Proteins; Tibia; Tumor Burden; Xenograft Model Antitumor Assays; Zoledronic Acid | 2009 |
The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pain; Proportional Hazards Models; Treatment Outcome; Zoledronic Acid | 2009 |
Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Male; Neoplasms; Orchiectomy; Placebos; Prostatic Neoplasms; Risk Factors; Zoledronic Acid | 2010 |
Results of the Zometa cost-utility model for the german healthcare system based on the results of the ABCSG-12 study.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Female; Germany; Goserelin; Humans; Imidazoles; Markov Chains; Monte Carlo Method; Multicenter Studies as Topic; National Health Programs; Neoplasms, Multiple Primary; Nitriles; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2010 |
Serum C-telopeptide levels predict the incidence of skeletal-related events in cancer patients with secondary bone metastases.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Biomarkers, Tumor; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Collagen Type I; Diphosphonates; Disease Progression; Female; Fractures, Spontaneous; Humans; Imidazoles; Male; Middle Aged; Neoplasms; Peptides; Prognosis; Prospective Studies; Statistics, Nonparametric; Zoledronic Acid | 2010 |
Bisphosphonate-associated osteonecrosis of the jaws: surgical treatment with ErCrYSGG-laser. Case report.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Imidazoles; Jaw Diseases; Laser Therapy; Lasers, Solid-State; Low-Level Light Therapy; Mandibular Diseases; Middle Aged; Osteonecrosis; Photochemotherapy; Surgical Wound Dehiscence; Wound Healing; Zoledronic Acid | 2010 |
Gorham-Stout syndrome of the pelvic girdle treated by radiation therapy: a case report.
Topics: Bone Density Conservation Agents; Combined Modality Therapy; Diphosphonates; Disease Progression; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Magnetic Resonance Imaging; Mobility Limitation; Osteolysis, Essential; Pain Measurement; Pelvic Bones; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Young Adult; Zoledronic Acid | 2011 |
"Disappointing" trial results offer hope for older women with breast cancer.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Estrogens; Female; Humans; Imidazoles; Menopause; Neoplasm Recurrence, Local; Treatment Failure; Zoledronic Acid | 2011 |
Combination therapy inhibits development and progression of mammary tumours in immunocompetent mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Cell Proliferation; Diphosphonates; Disease Models, Animal; Disease Progression; Doxorubicin; Female; Imidazoles; Immunocompetence; Macrophages; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Zoledronic Acid | 2012 |
Bisphosphonate-associated osteonecrosis of the jaw: a six-year history of a case.
Topics: Bone Density Conservation Agents; Debridement; Diphosphonates; Disease Progression; Follow-Up Studies; Humans; Imidazoles; Immunoglobulin kappa-Chains; Male; Mandibular Diseases; Mandibular Neoplasms; Middle Aged; Multiple Myeloma; Osteonecrosis; Recurrence; Zoledronic Acid | 2011 |
Transcriptome analysis and in vivo activity of fluvastatin versus zoledronic acid in a murine breast cancer metastasis model.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Disease Progression; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; Indoles; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Metastasis; Transcriptome; Zoledronic Acid | 2012 |
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Bone Neoplasms; Cost-Benefit Analysis; Denosumab; Diphosphonates; Disease Progression; Health Expenditures; Humans; Imidazoles; Male; Markov Chains; Models, Econometric; Prostatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Survival Analysis; United States; Zoledronic Acid | 2013 |
Normal bone turnover markers in a patient with active Paget's disease of bone: response to treatment with zoledronic acid.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Disease Progression; Fatal Outcome; Female; Health Status; Heart Failure; Humans; Imidazoles; Osteitis Deformans; Treatment Outcome; Zoledronic Acid | 2012 |
Denosumab for the treatment of bisphosphonate-refractory hypercalcemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Neoplasms; Carcinoma, Renal Cell; Denosumab; Diphosphonates; Disease Progression; Drug Resistance; Fatal Outcome; Humans; Hypercalcemia; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Parathyroid Hormone; Risk Assessment; Zoledronic Acid | 2012 |
Intravenous bisphosphonate-related osteonecrosis of the jaw: long-term follow-up of 109 patients.
Topics: Adult; Aged; Aged, 80 and over; Bisphosphonate-Associated Osteonecrosis of the Jaw; Chi-Square Distribution; Comorbidity; Diabetes Mellitus; Diphosphonates; Disease Progression; DMF Index; Female; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; New York City; Pamidronate; Risk Factors; Smoking; Zoledronic Acid | 2013 |
Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cohort Studies; Diphosphonates; Disease Progression; Female; Fractures, Spontaneous; Humans; Imidazoles; Middle Aged; Musculoskeletal Pain; Palliative Care; Retrospective Studies; Treatment Outcome; Young Adult; Zoledronic Acid | 2013 |
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Topics: Aged; Aged, 80 and over; Calcitriol; Carcinoma; Cohort Studies; Dexamethasone; Diphosphonates; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Follow-Up Studies; Humans; Imidazoles; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostatic Neoplasms; Pulse Therapy, Drug; Risk Assessment; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2004 |
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Drug Administration Schedule; Female; Humans; Imidazoles; Infusions, Intravenous; Kidney Neoplasms; Male; Neoplasm Staging; Prognosis; Sampling Studies; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2004 |
Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells.
Topics: Antimetabolites; Antineoplastic Agents; Cell Cycle; Clodronic Acid; Diphosphonates; Disease Progression; Humans; Imidazoles; Melanoma; Nitrogen; Pamidronate; Skin Neoplasms; Tumor Cells, Cultured; Zoledronic Acid | 2004 |
High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Dexamethasone; Diphosphonates; Disease Progression; Humans; Imidazoles; Male; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2004 |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2005 |
Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Squamous Cell; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Lung Neoplasms; Middle Aged; Osteoarthropathy, Secondary Hypertrophic; Zoledronic Acid | 2005 |
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.
Topics: Aged; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Disease Progression; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Pamidronate; Retrospective Studies; Time Factors; Treatment Outcome; Zoledronic Acid | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Diphosphonates; Disease Progression; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Remission Induction; Risedronic Acid; Zoledronic Acid | 2005 |
Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Caspase 1; Caspase 3; Caspases; Cell Cycle; Cell Proliferation; Chemotherapy, Adjuvant; Chondrosarcoma; Curettage; Diphosphonates; Disease Progression; Imidazoles; Male; Neoplasm Recurrence, Local; Rats; Rats, Sprague-Dawley; Survival Analysis; Zoledronic Acid | 2006 |
Therapeutic role of bisphosphonate and radiation combination in the management of myeloma bone disease.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Cell Cycle; Combined Modality Therapy; Diphosphonates; Disease Progression; Humans; Imidazoles; Multiple Myeloma; Orthopedics; Radiopharmaceuticals; Zoledronic Acid | 2007 |
Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Case-Control Studies; Cathepsin K; Cathepsins; Cystatin C; Cystatins; Diphosphonates; Disease Progression; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Prostatic Hyperplasia; Prostatic Neoplasms; ROC Curve; Zoledronic Acid | 2008 |
Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Disease Progression; Flow Cytometry; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Microscopy, Phase-Contrast; Neoplasms, Experimental; Survival Rate; Treatment Outcome; Zoledronic Acid | 2008 |
Paget disease of the spine manifested by thoracic and lumbar epidural lipomatosis: magnetic resonance imaging findings.
Topics: Bone Density Conservation Agents; Decompression, Surgical; Diphosphonates; Disease Progression; Epidural Space; Humans; Imidazoles; Laminectomy; Lipomatosis; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Osteitis Deformans; Paraparesis; Recurrence; Spinal Diseases; Spinal Stenosis; Thoracic Vertebrae; Treatment Outcome; Zoledronic Acid | 2007 |
The effects of MMP inhibitors on human salivary MMP activity and caries progression in rats.
Topics: Analysis of Variance; Animals; Dental Caries; Dentin; Diphosphonates; Disease Progression; Female; Humans; Imidazoles; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Protease Inhibitors; Rats; Rats, Wistar; Salivary Proteins and Peptides; Statistics, Nonparametric; Tetracyclines; Zoledronic Acid | 2001 |